Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NASDAQ:ZYME) – Analysts at Lifesci Capital dropped their Q1 2026 earnings per share (EPS) estimates for Zymeworks in a report issued on Monday, March 2nd. Lifesci Capital analyst C. Zhu now anticipates that the company will post earnings of ($0.52) per share for the quarter, down from their previous forecast of $0.55. Lifesci Capital also issued estimates for Zymeworks’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($0.68) EPS.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $21.78 million. During the same period in the prior year, the business earned ($0.31) EPS. The company’s quarterly revenue was down 91.9% on a year-over-year basis.

Other analysts have also issued research reports about the stock. Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $25.00 to $33.00 in a research note on Friday, December 12th. Truist Financial started coverage on shares of Zymeworks in a research report on Wednesday, December 17th. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright increased their price objective on shares of Zymeworks from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Citigroup started coverage on shares of Zymeworks in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Finally, Leerink Partners upped their target price on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.70.

Zymeworks Trading Down 1.7%

ZYME stock opened at $24.80 on Thursday. The stock’s 50 day simple moving average is $23.78 and its 200 day simple moving average is $21.01. Zymeworks has a 12-month low of $9.03 and a 12-month high of $28.49. The firm has a market cap of $1.83 billion, a P/E ratio of -22.96 and a beta of 1.23.

Institutional Trading of Zymeworks

Several large investors have recently added to or reduced their stakes in the business. Optiver Holding B.V. acquired a new position in shares of Zymeworks during the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in Zymeworks in the 4th quarter valued at approximately $37,000. Quarry LP bought a new position in Zymeworks in the 3rd quarter worth approximately $50,000. Tower Research Capital LLC TRC lifted its holdings in shares of Zymeworks by 29.6% during the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after buying an additional 1,131 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Zymeworks by 25.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock worth $96,000 after buying an additional 731 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Mark Hollywood sold 6,120 shares of Zymeworks stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $138,740.40. Following the sale, the chief operating officer owned 132,913 shares of the company’s stock, valued at approximately $3,013,137.71. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey T. L. Smith sold 9,310 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $211,057.70. Following the transaction, the executive vice president owned 26,708 shares of the company’s stock, valued at approximately $605,470.36. This represents a 25.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is owned by company insiders.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Lifesci Capital raised several later-quarter and full‑year FY2026 EPS estimates (Q2, Q3, Q4 and FY2026 were revised to be materially less negative or positive), signaling improving expectations for Zymeworks’ 2026 profitability outlook. MarketBeat Analyst Note
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, and Leerink issued a bullish outlook — analyst upgrades and higher targets support upside sentiment and explain earlier intraday gains. Stifel Price Target Leerink Note
• Positive Sentiment: Media noted a short-term positive reaction to analyst upgrades (shares rose on upgrade headlines). Upgrade Reaction
• Neutral Sentiment: Consensus analyst stance remains constructive overall (average recommendation ~“Moderate Buy”), which provides informational support but not immediate fundamental change. Analyst Consensus
• Negative Sentiment: Recent Q4 results were a clear negative catalyst: EPS missed and revenue plunged year‑over‑year (top-line far below expectations), highlighting the volatility of Zymeworks’ milestone-driven model and near-term execution risk. This underpins profit worries despite longer-term analyst upgrades. FY25 Review / Q4 Analysis
• Negative Sentiment: Lifesci also lowered its Q1 2026 EPS forecast (from a prior positive to a negative), signaling near-term softness that likely offsets some of the enthusiasm from later‑year upgrades. MarketBeat Analyst Note

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.